Immune Checkpoint Inhibitors Market Expected to Reach $56,530 Million by 2025


quote Increase in prevalence of cancer and high efficacy of immune checkpoint inhibitors play a major role in the growth of the market. Furthermore, increase in awareness of checkpoint inhibitor drugs in the developing countries is expected to boost their demand in the coming years. quote

Pallavi Jaiswal
Senior Analyst, Healthcare Research at AMR.

Get 20% Free Customization In This Report
Follow us on Social Media:       

According to a new report published by Allied Market Research, titled, Immune Checkpoint Inhibitors Market, by Type and Application: Global Opportunity Analysis and Industry Forecast, 2018-2025," the global immune checkpoint inhibitors market was valued at $10,566 million in 2017, and is expected to reach $56,530 million by 2025, growing at a CAGR of 20.1% from 2018 to 2025.

Immune checkpoint inhibitor targets checkpoint proteins and assists the immune system to recognize and attack cancer cells. Immune checkpoint inhibitors are expected to exhibit significant market growth during the forecast period, due to upsurge in demand for ideal therapeutics for the treatment of cancer, favorable reimbursement policies provided by manufacturers & insurance providers in some countries, and surge in prevalence of cancer across the globe.

Based on type, the global immune checkpoint inhibitors market is categorized into CTLA-4 inhibitor, PD-1 inhibitor, PD-L1 inhibitor, and others. The PD-1 inhibitor segment was the major revenue contributor in 2017, and is anticipated to continue this trend during the forecast period, due to increase in adoption of PD-1 inhibitors such as pembrolizumab and nivolumab globally. However, PD-L1 inhibitor segment is projected to exhibit the fastest growth during the forecast period, owing to rise in use of durvalumab & avelumab and surge in R&D for combination studies of PD-L1 inhibitors for newer indications.

By application, the market is classified into lung cancer, bladder cancer, melanoma, Hodgkin lymphoma, and others. The lung cancer segment presently dominates the market, and is expected to remain dominant during the forecast period, due to increase in use of immune check point inhibitors for the treatment of lung cancer and surge in prevalence of lung cancer globally. However, the bladder cancer segment is projected to show fastest growth during the forecast period, due to increase in incidence of bladder cancer.

Key Findings of the Immune Checkpoint Inhibitors Market:

  • The PD-L1 inhibitor segment is expected to experience rapid growth, registering a CAGR of 34.2% from 2018 to 2025.
  • The lung cancer segment held nearly two-fifths global market share in 2017, and is expected to remain dominant throughout the forecast period.
  • Asia-Pacific is estimated to grow at a CAGR of 22.1% during the forecast period.

North America accounted for more than half of the global market share in 2017, and is expected to remain dominant throughout the forecast period. This is attributed to increase in demand for immune checkpoint inhibitors, high prevalence of cancer, rise in number of trained medical professionals, and supportive reimbursement policies in the healthcare system. However, Asia-Pacific is expected to experience the highest growth rate during the forecast period, majorly due to upsurge in prevalence of cancer coupled with increase in adoption of immune checkpoint inhibitors.

The key players profiled in this report include AstraZeneca PLC., Bristol-Myers Squibb Company, Eli Lilly and Company (ARMO Biosciences.), Fortress Biotech, Inc. (Checkpoint Therapeutics, Inc.), F. Hoffmann-La Roche Ltd. (Genentech, Inc.), Immutep Limited, Merck & Co., Inc., Merck KGaA (EMD Serono, Inc.), Novartis AG, and Pfizer Inc.

Need More Information

pr-det-talk Talk to David (Europe)

pr-det-talk Talk to Sona Padman (Americas)

5933 NE Win Sivers Drive #205,
Portland, OR 97220 United States

pr-det-phone Toll Free: +1-800-792-5285

pr-det-phone UK: +44-845-528-1300

pr-det-phone Hong Kong: +852-301-84916

pr-det-phone India (Pune): +91 2066346060

pr-det-phone Fax: +1(855) 550-5975

pr-det-phone help@alliedmarketresearch.com


For Media Inquiries, Please Contact

Ram D
Communications Officer
Allied Market Research
Contact Toll Free: +1-800-792-5285
Drop us an email at


First time buyer?
Check offers and discount on this report
To get this report

Click Here

quote Immune Checkpoint Inhibitors Market by Type (CTLA-4 Inhibitor, PD-1 Inhibitor, and PD-L1 Inhibitor) and Application (Lung Cancer, Bladder Cancer, Melanoma, Hodgkin Lymphoma, and Others) - Global Opportunity Analysis and Industry Forecast, 2018-2025 quote

View Report

Avenue: Entire Library membership of Allied Market Research Reports at your disposal

  • Avenue is an innovative subscription-based online report database.
  • Avail an online access to the entire library of syndicated reports on more than 2,000 niche industries and company profiles on more than 12,000 firms across 11 domains.
  • A cost-effective model tailored for entrepreneurs, investors, and students & researchers at universities.
  • Request customizations, suggest new reports, and avail analyst support as per your requirements.
  • Get an access to the library of reports at any time from any device and anywhere.


Why Allied Market Research?


Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction


On-demand customization of scope of the report to exactly meet your needs

Targeted Market View

Targeted market view to provide pertinent information and save time of readers


Featured Readings


Get Fresh content delivered

Get insights on topics that matter to your business. Stay updated on the area that interests you.

Get Industry Data Alerts

Buy Full Version
"Immune Checkpoint Inhibitors Market"
Purchase Enquiry